Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations

Hannah Goulart, Hagop M. Kantarjian, Lucia Masarova, Naval Daver, Elias Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Courtney D. DiNardo, Sherry Pierce, Lingsha Zhou, Mahesh Swaminathan, Gautam Borthakur, Nitin Jain, Prithviraj Bose, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2024-202606

Published: 2024

Journal Articles

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Blood (2021) 138 (Supplement 1): 144.

https://doi.org/10.1182/blood-2021-150908

Published: 2021

Journal Articles

Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Zeev E. Estrov, Hagop Kantarjian, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2021-154267

Published: 2021

Journal Articles

Characteristics and Outcome of Myelofibrosis Patients on Long-Term Ruxolitinib Therapy (≥3 years)

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142554

Published: 2020

Journal Articles

Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms

Sangeetha Venugopal, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Lucia Masarova, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-143131

Published: 2020

Journal Articles

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Daniel Rivera, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Lucia Masarova, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142650

Published: 2020

Journal Articles

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140441

Published: 2020

Journal Articles

Improved Survival of Patients with Myelofibrosis in the Last Decade

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-142578

Published: 2020

Journal Articles

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Blood (2019) 134 (Supplement_1): 555.

https://doi.org/10.1182/blood-2019-130046

Published: 2019

Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood (2019) 134 (Supplement_1): 4237.

https://doi.org/10.1182/blood-2019-125974

Published: 2019

Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Blood (2019) 134 (Supplement_1): 1656.

https://doi.org/10.1182/blood-2019-130691

Published: 2019

Journal Articles

Evaluation of Cytogenetic Stratifications in Myelofibrosis

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Zeev E. Estrov, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2018) 132 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2018-99-120225

Published: 2018

Journal Articles

Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study

Lucia Masarova, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2018) 132 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2018-99-120203

Published: 2018

Journal Articles

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Blood (2018) 132 (Supplement 1): 687.

https://doi.org/10.1182/blood-2018-99-119753

Published: 2018

Journal Articles

Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph David Khoury, MD, Susan M. O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Naumovich Konoplev, MD PhD, Keyur Patel, MD PhD, Sherry A. Pierce, BSN, BA, Lingsha Zhou, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2018-99-119888

Published: 2018

Journal Articles

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Lucia Masarova, MD, Srdan Verstovsek, MD PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Maro N. Ohanian, DO, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Romany Gergis, Gautam Borthakur, MD, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Naval G. Daver, MD

Blood (2018) 132 (Supplement 1): 352.

https://doi.org/10.1182/blood-2018-99-120251

Published: 2018

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)

Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kurt Schroeder, Alessandra Ferrajoli, MD, Elias J. Jabbour, MD, Naval Daver, MD, Courtney D. DiNardo, MDMSc, Yesid Alvarado, MD, Musa Yilmaz, MD, Julie Huynh-Lu, Physician Assistant, Wei Qiao, PhD, Xuemei Wang, Aurelio Matamoros, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 1632.

https://doi.org/10.1182/blood.V130.Suppl_1.1632.1632

Published: 2017

Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 255.

https://doi.org/10.1182/blood.V130.Suppl_1.255.255

Published: 2017

Journal Articles

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Tapan Kadia, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Zeev Estrov, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lingsha Zhou, Po Yee Mak, Karina Salinas, RN, Carla Kay Tuttle, RN, Sherry Pierce, BSN, BA, Uday Popat, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 256.

https://doi.org/10.1182/blood.V130.Suppl_1.256.256

Published: 2017

NARROW

Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils

Characteristics and Outcome of Myelofibrosis Patients on Long-Term Ruxolitinib Therapy (≥3 years)

Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Improved Survival of Patients with Myelofibrosis in the Last Decade

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Evaluation of Cytogenetic Stratifications in Myelofibrosis

Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only